Samuel Kintz, PRESIDENT AND CEO at Enliven Therapeutics, Inc. (ELVN), sold 23,422 shares at $21.63 ($507K) on 2024-06-25, disclosed to the SEC on 2024-06-27.
Scheduled sale ($507k) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.63 | 11,422 | $247K | 48.7% |
| 2 | $21.63 | 11,422 | $247K | 48.7% |
| 3 | $22.30 | 578 | $13K | 2.5% |
| Total | $21.65 avg | 23,422 | $507K | 100% |
| Filing → |
| ELVN | SELL | 2025-09-30 | $74K | — | Filing → |
| ELVN | SELL | 2025-09-25 | $56K | — | Filing → |
| ELVN | SELL | 2025-09-19 | $116K | — | Filing → |